X-Gen Tablets 400Mg (1 Box = 1 Strip)(1 Strip = 5 Tablets)

Moxifloxacin has in vitro activity against a wide range of Gram-positive and Gram-negative microorganisms

PKR 500.00

PKR 475.00

You save: PKR 25.00

Quantity:

SKU: X_GEN_TABLETS_400MG_5S_NV

Category: Medicines

Moxifloxacin has in vitro activity against a wide range of Gram-positive and Gram-negative microorganisms. The bactericidal action of moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) and topoisomerase IV required for bacterial DNA replication, transcription, repair, and recombination. It appears that the C8-methoxy moiety contributes to enhanced activity and lower selection of resistant mutants of Gram-positive bacteria compared to the C8-H moiety. The presence of the bulky bicycloamine substituent at the C 7 position prevents active efflux, associated with the NorA or pmrA genes seen in certain Gram-positive bacteria.

Purpose

Bacterial Infection

Ingredients

Moxifloxacin HCl

Warnings

Moxifloxacin has been shown to prolong the QT interval of the electrocardiogram in some patients. The drug is advised to be avoided in patients with known prolongation of the QT interval, patients with uncorrected hypokalemia and patients receiving Class IA (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic agents, due to the lack of clinical experience with the drug in these patient populations.
Moxifloxacin is advised to be used with caution in patients with ongoing proarrhythmic conditions, such as clinically significant bradycardia, acute myocardial ischemia. The magnitude of QT prolongation may increase with increasing concentrations of the drug or increasing rates of infusion of the intravenous formulation. Therefore the recommended dose or infusion rate is advised to not be exceeded.
Convulsions have been reported in patients receiving quinolones. Quinolones may also cause central nervous system (CNS) events including: dizziness, confusion, tremors, hallucinations, depression and rarely, suicidal thoughts or acts. These reactions may occur following the first dose. If these reactions occur in patients receiving moxifloxacin, the drug is advised to be discontinued and appropriate measures instituted.

Side Effects

BODY AS A WHOLE: Abdominal pain, headache, asthenia, injection site reaction (including phlebitis), malaise, moniliasis, pain, allergic reaction CARDIOVASCULAR: Tachycardia, palpitation, vasodilation, QT interval prolonged DIGESTIVE: Vomiting, abnormal liver function test, dyspepsia, dry mouth, flatulence, oral moniliasis, constipation, GGTP increased, anorexia, stomatitis, glossitis HEMIC AND LYMPHATIC: Leukopenia, eosinophilia, prothrombin decrease (prothrombin time prolonged/International Normalized Ratio (INR) increased), thrombocythemia METABOLIC AND NUTRITIONAL: Lactic dehydrogenase increased, amylase increased MUSCULOSKELETAL: Arthralgia, myalgia NERVOUS SYSTEM: Insomnia, nervousness, vertigo, somnolence, anxiety, tremor SKIN/APPENDAGES: Rash (maculopapular, purpuric, pustular), pruritus, sweating, urticaria SPECIAL SENSES: Taste perversion.